Escitalopram and neuroendocrine response in healthy first-degree relatives to depressed patients - a randomized placebo-controlled trial

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Knorr, Ulla ^a,c   Vinberg, Maj ^a   Hansen, Allan ^a   Klose, Marianne ^a   Feldt Rasmussen, Ulla ^a   Hilsted, Linda ^a   Hasselstrøm, Jørgen ^b   Gether, Ulrik ^c   Winkel, Per ^a   Gluud, Christian ^a   Wetterslev, Jørn ^a   Kessing, Lars Vedel ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; ESCITALOPRAM; HYDROCORTISONE; PLACEBO; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG RESPONSE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; NAUSEA; NORMAL HUMAN; ORGASM DISORDER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RELATIVE; RESTLESSNESS; SWEAT GLAND DISEASE; TREMOR; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FAMILY; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FAMILY; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; YOUNG ADULT;

EID: 79959655098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021224     Document Type: Article

References (40)

1. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, et al. (2005) The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 1085-1093.
2. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, et al. (1998) Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18: 253-262.
3. Halligan SL, Herbert J, Goodyer IM, Murray L, (2004) Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry 55: 376-381.
4. Mannie ZN, Harmer CJ, Cowen PJ, (2007) Increased waking salivary cortisol levels in young people at familial risk of depression. Am J Psychiatry 164: 617-621.
5. Vinberg M, Bennike B, Kyvik KO, Andersen PK, Kessing LV, (2008) Salivary cortisol in unaffected twins discordant for affective disorder. Psychiatry Res 161: 292-301.
6. Fuller RW, Snoddy HD, (1990) Serotonin receptor subtypes involved in the elevation of serum corticosterone concentration in rats by direct- and indirect-acting serotonin agonists. Neuroendocrinology 52: 206-211.
7. Jensen JB, Jessop DS, Harbuz MS, Mork A, Sanchez C, et al. (1999) Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11: 465-471.
8. Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, et al. (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14: 253-263.
9. Bhagwagar Z, Hafizi S, Cowen PJ, (2002) Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology (Berl) 163: 118-120.
10. Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, et al. (2004) Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) 177: 200-206.
11. Nadeem HS, Attenburrow MJ, Cowen PJ, (2004) Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. Neuropsychopharmacology 29: 1699-1703.
12. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, et al. (2005) Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology (Berl) 178: 268-275.
13. Jongsma ME, Bosker FJ, Cremers TI, Westerink BH, Den Boer JA, (2005) The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychiatry 29: 738-744.
14. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R, (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
15. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet.
16. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, et al. (2007) Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression- a potential biomarker? Biol Psychiatry 62: 47-54.
17. Robins E, Guze SB, (1970) Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 126: 983-987.
18. Kendell RE, (1989) Clinical validity. Psychol Med 19: 45-55.
19. Gould TD, Gottesman II, (2006) Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 5: 113-119.
20. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK, (2006) Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60: 93-105.
21. Knorr U, Kessing LV, (2010) The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nord J Psychiatry.
22. Knorr U, Vinberg M, Klose M, Feldt-Rasmussen U, Hilsted L, et al. (2009) Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials 10: 66.
23. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al. (1990) SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47: 589-593.
24. Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV, (2009) Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemol Ment Health 5: 4.
25. The Structured Clinical Interview for DSM- IV Axis II Personality Disorders (SCID- II) American Psychiatric Press, Washington DC.
26. Bech P, Kastrup M, Rafaelsen OJ, (1986) Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 326: 1-37.
27. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, et al. (2001) Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 55 (Suppl 44): 5-69.
28. Gotzsche PC, (1996) Blinding during data analysis and writing of manuscripts. Control Clin Trials 17: 285-290.
29. ICH Harmonised Tripartite Guideline (1999) Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 18: 1905-1942.
30. Sullivan LM, Dukes KA, Losina E, (1999) Tutorial in biostatistics. An introduction to hierarchical linear modelling. Stat Med 18: 855-888.
31. Winkel P, Zhang NF, (2007) Statistical development of quality in medicine John Wiley & Sons, Chichester.
32. Heuser I, Yassouridis A, Holsboer F, (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356.
33. Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, et al. (2006) Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. Neuropsychopharmacology 31: 212-220.
34. Bech P, Andersen HF, Wade A, (2006) Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 39: 128-134.
35. Gluud C, (2006) The culture of designing hepato-biliary randomised trials. J Hepatol 44: 607-615.
36. Gluud LL, (2006) Bias in clinical intervention research. Am J Epidemiol 163: 493-501.
37. Guyatt GH, Mills EJ, Elbourne D, (2008) In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med 5: e4.
38. Sogaard B, Mengel H, Rao N, Larsen F, (2005) The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 45: 1400-1406.
39. Schule C, Baghai TC, Eser D, Hafner S, Born C, et al. (2009) The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One 4: e4324.
40. Hasler G, Drevets WC, Manji HK, Charney DS, (2004) Discovering endophenotypes for major depression. Neuropsychopharmacology 29: 1765-1781.